## Contents

Subject Index &middot; i
Countries and Institutions &middot; ii
Contributors &middot; iv
Contributions &middot; iv
Case List &middot; v

### Subject Index

#### COMPETITION

**Dominance**
- Highest Italian administrative court has the final word on the Xalatan case and reinstates the original infringement decision of the Italian Competition Authority (Case Comment) 6 219

**Pharmaceuticals**
- Reverse payment settlement agreements in the pharmaceutical industry: settling the debate between the pro-exclusivity principles of patent law and the pro-competition principles of antitrust law (Article) 6 195

#### DEVELOPING COUNTRIES

**Patents**
- Patents and access to medicine in the developing world: a call for broader engagement (Editorial) 3 87

#### DISCLOSURE

**Clinical trial data**
- Transparency of clinical trial data: current state of play (Article) 6 204

#### EQUITY CAPITAL MARKETS

**Capital raisings**
- Changes to facilitate capital raisings in UK markets (United Kingdom) 2 86

#### GENETIC RESOURCES

**Regulation**
- Biodiversity laws: an emerging regulation on genetic resources or “IP on life” through the backdoor? (Article) 4 119

### GM CROPS

**Authorisation**
- Legal considerations related to the authorisation, import and cultivation of GM crops in the European Union: a precedent for other regulated industries? (Editorial) 5 155

### JURISDICTION

**Infringement**
- UK Court of Appeal opens the way for pan-European jurisdiction on infringement Actavis Group HF and Medis EHF v Eli Lilly and Company (Case Comment) 2 71

### MEDICINAL PRODUCTS

**Licensing**
- Meeting the needs of patients: early access and adaptive licensing (Editorial) 6 191

**Regulation**
- Falsified Medicines Directive (News) 1 27
- Protection for orphan medicinal products in the EU and controversies that have arisen under the EU regime (Article) 1 3

**Unauthorised medicines**
- Should cost prevail over safety? The risks of promoting unauthorised pharmaceuticals and off-label use for budgetary considerations (Article) 5 172

### PATENTS

**Access to medicine**
- Patents and access to medicine in the developing world: a call for broader engagement (Editorial) 3 87

**Experts**
- Instructing experts in patent litigation (Article) 5 161

**Gene patents**
- Isolated gene sequences and patentable subject-matter Cancer Voices Australia v Myriad Genetics Inc (News) 1 26
- Legal definition of human genes and patent eligibility in the light of the Myriad case (Article) 4 140
- US Supreme Court rules on BRCA1 and BRCA2 patents Association of Molecular Pathology v Myriad Genetics (Case Comment) 2 77
Infringement
Court of Appeal upholds the validity of Genentech patent (1) Regeneron Pharmaceuticals Inc. (2) Bayer Pharma AG v Genentech Inc. (Case Comment) 1 17
Highest Italian administrative court has the final word on the Xalatan case and reinstates the original infringement decision of the Italian Competition Authority (Case Comment) 6 219
UK IPO consultation on exemptions to patent infringement for clinical trials (Case Comment) 1 23

Injunctions
Teva's record of previous 'at risk' launches before patent expiry is deemed relevant to whether an injunction should be ordered against it Merck Sharp Dohme Corp and Another v Teva Pharma BV and Another (Case Comment) 4 147

Patentability
CJEU reference on meaning of 'human embryos': does it include parthenotes? International Stem Cell Corporation v Comptroller General of Patents (Case Comment) 2 68
 Exceptions to patentability: Australia v Europe (Article) 2 49
 Neural precursor cells II: decision of the German Supreme Court (Bundesgerichtshof) X ZR 58/07 (Brüstle/Greenpeace) (Case Comment) 1 21

Precursor cells
Neural precursor cells II: decision of the German Supreme Court (Bundesgerichtshof) X ZR 58/07 (Brüstle/Greenpeace) (Case Comment) 1 21

Seeds
US Supreme Court: unanimous ruling leaves open questions with respect to other self replicating technology and the conditional sale doctrine Bowman v Monsanto (Case Comment) 2 74

Supplementary Protection Certificates
Recent European developments regarding supplementary protection certificates (Case Comment) 5 178
Vaccines and SPCs: the CJEU reaches a fork in the road (Article) 2 35

Unified Patent Court
Unified Patent Court – shifting to a new paradigm (Article) 1 9
Unified Patent Court: the 16th draft rules of procedure: ten key developments (Case Comment) 6 215

Validity
Alzheimer's patent invalid for insufficiency – patents must be more than merely 'research projects' Eli Lilly and Co v Janssen Alzheimer Immunotherapy (Case Comment) 3 112
Court of Appeal upholds the validity of Genentech patent (1) Regeneron Pharmaceuticals Inc. (2) Bayer Pharma AG v Genentech Inc. (Case Comment) 1 17

Paediatric Regulation
Better medicines for children? What have been the benefits and lessons learned after five years of the Paediatric Regulation? (Article) 3 95

Pricing
UK Pharmaceutical Price Regulation Scheme (PPRS) and the statutory regulations: an overview and outline of how the schemes may impact the life sciences industry (Case Comment) 6 208

Unauthorised medicines
Should cost prevail over safety? The risks of promoting unauthorised pharmaceuticals and off-label use for budgetary considerations (Article) 5 172

PLANT VARIETIES
Protection regimes
Plant variety protection regimes and seed regulations in Sub-Saharan Africa: current trends and implications (Article) 3 101

TAX
New tax measures for 2013 offer tax saving opportunities for life sciences companies (UK News) 1 29

TECHNOLOGY AGREEMENTS
Licensing
Changes to technology licensing in Europe: new competition law analysis will affect existing licences and new negotiations (Article) 3 90

TRADE SECRETS
EU Directive
Uniform trade secrets protection for Europe? (Case Comment) 5 184

Countries and Institutions
AUSTRALIA
Patentability
Exceptions to patentability: Australia v Europe (Article) 2 49
Patents
Isolated gene sequences and patentable subject-matter Cancer Voices Australia v Myriad Genetics Inc (News) 1 26

BURKINA FASO
Plant variety protection
Plant variety protection regimes and seed regulations in Sub-Saharan Africa: current trends and implications (Article) 3 101
COURT OF JUSTICE OF THE EUROPEAN UNION (CJEU)

**Patents**
- Recent European developments regarding supplementary protection certificates (Case Comment) 5 178
- Vaccines and SPCs: the CJEU reaches a fork in the road (Article) 2 35

**EUROPEAN COMMISSION**

**Competition law**
- Changes to technology licensing in Europe: new competition law analysis will affect existing licences and new negotiations (Article) 3 90

**Paediatric Regulation**
- Better medicines for children? What have been the benefits and lessons learned after five years of the Paediatric Regulation? (Article) 3 95

**Trade secrets**
- Uniform trade secrets protection for Europe? (Case Comment) 5 184

**EUROPEAN UNION**

**Disclosure**
- Transparency of clinical trial data: current state of play (Article) 6 204

**Genetic resources**
- Biodiversity laws: an emerging regulation on genetic resources or 'IP on life' through the backdoor? (Article) 4 119

**GM crops**
- Legal considerations related to the authorisation, import and cultivation of GM crops in the European Union: a precedent for other regulated industries? (Editorial) 5 155

**Medicinal products**
- Falsified Medicines Directive (News) 1 27
- Protection for orphan medicinal products in the EU and controversies that have arisen under the EU regime (Article) 1 3

**Patents**
- Exceptions to patentability: Australia v Europe (Article) 2 49
- Unified Patent Court – shifting to a new paradigm (Article) 1 9
- Unified Patent Court: the 16th draft rules of procedure: ten key developments (Case Comment) 6 215

**Pharmaceuticals**
- Reverse payment settlement agreements in the pharmaceutical industry: settling the debate between the pro-exclusivity principles of patent law and the pro-competition principles of antitrust law (Article) 6 195
- Should cost prevail over safety? The risks of promoting unauthorised pharmaceuticals and off-label use for budgetary considerations (Article) 5 172

**GERMANY**

**Patents**
- Neural precursor cells II: decision of the German Supreme Court (Bundesgerichtshof) X ZR 58/07 (Brüstle/Greenpeace) (Case Comment) 1 21

**ITALY**

**Competition**
- Highest Italian administrative court has the final word on the Xalatan case and reinstates the original infringement decision of the Italian Competition Authority (Case Comment) 6 219

**TANZANIA**

**Plant variety protection**
- Plant variety protection regimes and seed regulations in Sub-Saharan Africa: current trends and implications (Article) 3 101

**UNITED KINGDOM**

**Injunctions**
- Teva’s record of previous ‘at risk’ launches before patent expiry is deemed relevant to whether an injunction should be ordered against it Merck Sharp Dohme Corp and Another v Teva Pharma BV and Another (Case Comment) 4 147

**Jurisdiction**
- UK Court of Appeal opens the way for pan-European jurisdiction on infringement Actavis Group HF and Medis EHF v Eli Lilly and Company (Case Comment) 2 71

**Medicinal products**
- Falsified Medicines Directive (News) 1 27

**Patents**
- Alzheimer’s patent invalid for insufficiency – patents must be more than merely ‘research projects’ Eli Lilly and Co v Janssen Alzheimer Immunotherapy (Case Comment) 3 112
- CJEU reference on meaning of ‘human embryos’: does it include parthenotes? International Stem Cell Corporation v Comptroller General of Patents (Case Comment) 1 58
- Court of Appeal upholds the validity of Genentech patent (1) Regeneron Pharmaceuticals Inc. (2) Bayer Pharma AG v Genentech Inc. (Case Comment) 1 17
- Instructing experts in patent litigation (Article) 5 161
- UK IPO consultation on exemptions to patent infringement for clinical trials (Case Comment) 1 23

**Pharmaceuticals**
- UK Pharmaceutical Price Regulation Scheme (PPRS) and the statutory regulations: an overview and outline of how the schemes may impact the life sciences industry (Case Comment) 6 208

**Tax**
- New tax measures for 2013 offer tax saving opportunities for life sciences companies (News) 1 29

**UNITED STATES**

**Patents**
- Legal definition of human genes and patent eligibility in the light of the Myriad case (Article) 4 140
- US Supreme Court rules on BRCAs and BRC2 patents Association of Molecular Pathology v Myriad Genetics (Case Comment) 2 77
- US Supreme Court: unanimous ruling leaves open questions with respect to other self replicating technology and the conditional sale doctrine Bowman v Monsanto (Case Comment) 2 74

**Pharmaceuticals**
- Reverse payment settlement agreements in the pharmaceutical industry: settling the debate between the pro-exclusivity principles of patent law and the pro-competition principles of antitrust law (Article) 6 195
Contributors
Abrahams, Darren (Editorial) 5 155
Balfour, Laura (Article) 3 90
Ball, Jonathan (Case Comment) 4 147
Berghé, Pascal (Article) 5 172
Blakeney, Michael (Book Review) 2 79
Brindley, Conor (News) 1 29
Cline, Helen (Case Comment) 6 208
Cohen, Simon (Articles) 2 35, 5 161
Cook, Trevor (Article) 1 3
Cox, David (News) 1 26
Curley, Duncan (Book Review) 1 31
De Jonge, Bram (Article) 3 101
Del-Greco, Joseph (Article) 6 195
Dodds-Smith, Ian (Article) 6 204
Douma, Tijbbe (Case Comment) 5 178
England, Paul (Articles) 2 35, 5 161; (Case Comments) 5 184, 6 215
Farmer, Stacey (Case Comment) 1 21
Fullwood, Louise (News) 1 27
Giannino, Michele (Case Comment) 6 219
Gilbert, Penny (Case Comment) 2 71
Grund, Martin (Case Comment) 1 21
Herrlinger, Christoph (Article) 4 119
Hill, Christian (Case Comment) 6 208
Jones, Nigel (Editorial) 3 87; (Book Review) 4 151
Kallisanath, Vinita (Case Comments) 2 74, 2 77
Kapetanaki, Natalia A (Article) 4 140
Kempton, Luke (Case Comment) 1 23
Kempton, Nick (Case Comment) 2 71
Killick, James (Article) 5 172
Kock, Michael A (Article) 4 119
Kokke, Margot (Case Comment) 5 178
Kuijpers, Gertjan (Case Comment) 5 178
Lambrix, Ellen (Article) 3 90
Mahop, Marcelin (Article) 3 101
Mester, Gabor (Case Comment) 5 172
Middlemiss, Susie (Article) 3 90
Mills, Oliver (Article) 2 49
Mulryne, Jackie (Article) 6 204
Munyi, Peter (Article) 3 101
Nickless, David (Case Comment) 3 112
O’Leary, Julianne (Article) 2 68
O’Sullivan, Nina (Case Comments) 1 17, 2 68
Ranson, Paul (Editorial) 6 191; (Case Comment) 6 208
Rhodes, Daniel (Book Review) 4 151
Roberts, Tim (Book Reviews) 2 82, 3 115
Sant, David (Article) 1 9
Strachan, Grant (Article) 5 95

Contributions
EDITORIALES
Legal considerations related to the authorisation, import and
cultivation of GM crops in the European Union: a precedent for
other regulated industries? Darren Abrahams 5 155
Meeting the needs of patients: early access and adaptive licensing
Paul Ranson 6 191
Patents and access to medicine in the developing world:
a call for broader engagement Nigel Jones 3 87

ARTICLES
Better medicines for children? What have been the benefits and
lessons learned after five years of the Paediatric Regulation?
Grant Strachan 3 95
Biodiversity laws: an emerging regulation on genetic
resources or ‘IP on life’ through the backdoor?
Christoph Herrlinger and Michael A Kock 4 119
Changes to technology licensing in Europe: new competition law
analysis will affect existing licences and new negotiations
Laura Balfour, Ellen Lambrix and Susie Middlemiss 3 90
Exceptions to patentability: Australia v Europe
Dr Oliver Mills 2 49
Instructing experts in patent litigation Simon Cohen
and Paul England 5 161
Legal definition of human genes and patent eligibility in the light of the
Myriad case Natalia A Kapetanaki 4 140
Plant variety protection regimes and seed regulations in
Sub-Saharan Africa: current trends and implications
Marcelin Tonye Mahop, Bram de Jonge and Peter Munyi 3 101
Protection for orphan medicinal products in the EU and
controversies that have arisen under the EU regime
Trevor Cook 1 3
Reverse payment settlement agreements in the pharmaceutical
industry: settling the debate between the pro-exclusivity
principles of patent law and the pro-competition principles of
antitrust law Julianne O’Leary and Joseph Del-Greco 6 195
Should cost prevail over safety? The risks of promoting
unauthorised pharmaceuticals and off-label use for budgetary
considerations James Killick and Pascal Berghe 5 172
Transparency of clinical trial data: current state of play
Ian Dodds-Smith and Jackie Mulryne 6 204
Unified Patent Court – shifting to a new paradigm David Sant 1 9
Vaccines and SPCs: the CJEU reaches a fork in the road
Simon Cohen and Paul England 2 35

CASE COMMENTS
Alzheimer’s patent invalid for insufficiency – patents must be more
than merely ‘research projects’ Eli Lilly and Co v Jansen
Alzheimer Immunotherapy, David Nickless 3 112
CJEU reference on meaning of ‘human embryos’: does it include
parthenotes? International Stem Cell Corporation v Comptroller
General of Patents, Nina O’Sullivan 2 68
Court of Appeal upholds the validity of Genentech patent
(1) Regeneron Pharmaceuticals Inc. (2) Bayer Pharma AG v
Genentech Inc., Nina O’Sullivan 1 17
Highest Italian administrative court has the final word
on the Xalatan case and reinstates the original infringement
decision of the Italian Competition Authority
Michele Giannino 6 219
Neural precursor cells II: decision of the German Supreme Court
(Bundesgerichtshof) X ZR 58/07 (Brüstle/Greenpeace)
Dr Gabor Mester, Dr Stacey Farmer and Dr Martin Grund 1 21
Recent European developments regarding supplementary
protection certificates Gertjan Kuipers, Tijbbe Douma and
Margot Kokke 5 178
Teva’s record of previous ‘at risk’ launches before patent expiry is
deemed relevant to whether an injunction should be ordered
against it Merck Sharp Dohme Corp and Another v Teva Pharma
BV and Another, Jonathan Boll 4 147
UK Court of Appeal opens the way for pan-European jurisdiction on infringement Actavis Group HF and Medis EHF v Eli Lilly and Company, Nick Kempton and Penny Gilbert 2 71
UK IPO consultation on exemptions to patent infringement for clinical trials Luke Kempton 1 23
UK Pharmaceutical Price Regulation Scheme (PPRS) and the statutory regulations: an overview and outline of how the schemes may impact the life sciences industry Christian Hill, Paul Ranson and Helen Cline 6 208
Uniform trade secrets protection for Europe? Paul England 5 184
US Supreme Court rules on BRCAs and BRCAs2 patents Association of Molecular Pathology v Myriad Genetics, Vinita Kallisananath 2 77
US Supreme Court: unanimous ruling leaves open questions with respect to other self replicating technology and the conditional sale doctrine Bowman v Monsanto, Vinita Kallisananath 2 74

BOOK REVIEWS
All That Matters – Bioethics (Donna Dickenson) Tim Roberts 2 82
Crop Genetic Resources as a Global Commons. Challenges in International Law and Governance (Michael Halewood, Isabel Lopez Noriega and Selim Louafi, eds) Michael Blakeney 2 79
Medical Law – A Very Short Introduction (Charles Foster) Tim Roberts 3 115
Pharmaceutical Innovation, Competition and Patent Law – A Triilateral Perspective (Josef Drexl and Nari Lee, eds) Nigel Jones and Daniel Rhodes 4 151
Pharmaceutical, Biotechnology and Chemical Inventions – World Protection and Exploitation (Duncan Bucknell, ed., et al.) Dr Duncan Curley 1 31

Case List
Actavis v Sanofi (CJEU) Case C-443/12 5 178
Actavis Group HF and Medis EHF v Eli Lilly and Company [2013] EWCA Civ 517 2 71
Association of Molecular Pathology v Myriad Genetics (United States) June 13, 2013 569 U.S. ___ (2013) slip.op. at 1 2 77, 4 141
Bowman v Monsanto (United States) May 13, 2013 569 U.S. ___ (2013) slip.op. 2 74
Cancer Voices Australia v Myriad Genetics Inc (Australia) [2013] FCA 65 1 26
Eli Lilly v HGS (CJEU) Case C-403/12 5 178
Eli Lilly and Co v Janssen Alzheimer Immunotherapy [2013] EWHC 1737 (Pat) 3 112
FTC v Actavis, Inc. (United States) 133 S.Ct. 2223 (2013) 6 195
Georgetown II (CJEU) Case C-484/12 5 178
GlaxoSmithKlein Biological SA v Comptroller-General of Patents, Designs and Trade Marks [2013] EWHC 619 (Pat) 2 35
In the matter of Dr Oliver Brüstle v Greenpeace e.V. (Germany) Bundesgerichtshof X ZR 58/07 1 21
Italian Competition Authority (Autorità Garante della Concorrenza e del Mercato) v Pfizer et al. (Italian Supreme Administrative Court) Case 693/2014 12 February 2014 6 219
Lundbeck (European Commission) Case COMP/AT.39226 19 June 2013 6 195
Merck Sharp Dohme Corp and Another v Teva Pharma BV and Another [2013] EWHC 1958 (Pat) 9 July 2013 4 167
Oliver Brüstle v Greenpeace e.V. (CJEU) Case C-34/10 [2012] CMLR 41 2 68
Pioneer Hi-Bred International, Inc v Commission (EGC) Case T164/10 5 155
(1) Regeneron Pharmaceuticals Inc. v (2) Bayer Pharma AG v Genentech Inc. [2013] EWCA Civ 93 1 17
International Stem Cell Corporation v Comptroller General of Patents [2013] EWHC 807 (Ch) 2 68

© 2013 Lawtext Publishing Limited
Published by Lawtext Publishing Ltd, Office G18, Spinners Court, 55 West End, Witney, Oxon OX28 1NH, United Kingdom
Typeset by Deltatech Creative, Walderslade, Chatham, Kent
Printed in the United Kingdom by Information Press, Eynsham, Oxford